[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640423":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":33,"centralContacts":40,"locations":46,"responsibleParty":62,"collaborators":11,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":11,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":11,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":11,"overallStatus":83,"whyStopped":11,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Shanghai Jeyou Pharmaceutical Co., Ltd.","INDUSTRY",[8,14,17],{"label":9,"type":10,"description":11,"interventionNames":12},"JMKX000189 Dose 1","EXPERIMENTAL",null,[13],"Drug: JMKX000189",{"label":15,"type":10,"description":11,"interventionNames":16},"JMKX000189 Dose 2",[13],{"label":18,"type":19,"description":11,"interventionNames":20},"placebo","PLACEBO_COMPARATOR",[21],"Other: Placebo",[23,28],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"DRUG","JMKX000189","JMKX000189 administered orally.",[9,15],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":11},"OTHER","Placebo","Placebo administered orally.",[18],[34,38],{"name":35,"affiliation":36,"role":37},"Ruofan Huang","Huashan Hospital","PRINCIPAL_INVESTIGATOR",{"name":39,"affiliation":36,"role":37},"Xiaojie Wu",[41],{"name":42,"role":43,"phone":44,"phoneExt":11,"email":45},"Fawei Wu","CONTACT","+86 15720614080","wufawei@jeyoupharma.com",[47],{"facility":48,"status":11,"city":49,"state":11,"zip":11,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Huashan Hospital Fudan University","Shanghai","China","CN",{"type":53,"coordinates":54},"Point",[55,56],121.45806,31.22222,{"lat":56,"lon":55},[59],{"name":35,"role":43,"phone":60,"phoneExt":11,"email":61},"(+86)021-52888045","ruofanhuang@fudan.edu.cn",{"type":63,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100640423","phase-1-safety-and-efficacy-of-jmkx000189-for-chemotherapy-induced-peripheral-neuropathy-100640423",false,"NCT07601386","Safety and Efficacy of JMKX000189 for Chemotherapy-Induced Peripheral Neuropathy","A Phase Ib Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of JMKX000189 Tablets in Patients With Chemotherapy-Induced Peripheral Neuropathy","Inclusion Criteria:\n\n* Aged 18 to 75 years (inclusive), male or female.\n* Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2.\n* Life expectancy of ≥ 3 months.\n* Histologically or cytologically confirmed malignant solid tumors.\n* Investigator-confirmed diagnosis of CIPN accompanied with chemotherapy.\n* Adequate organ function.\n\nExclusion Criteria:\n\n* Presence of any type of peripheral neuropathy other than CIPN (e.g., diabetic, paraneoplastic, or nutritional).\n* Toxicities from prior anti-tumor therapy (excluding CIPN) \\> CTCAE Grade 1 within 2 weeks of first dose (excluding alopecia, skin pigmentation, stable hypothyroidism, or chronic events).\n* Participants with any of the following cardiovascular diseases or medical history:\n\n  1. Ischemic heart disease or myocardial infarction, unstable angina, coronary artery spasm, congestive heart failure (NYHA Class III-IV), cardiac arrest, stroke, or transient ischemic attack within 6 months;\n  2. Other clinically significant cardiac disorders per investigator's judgment.\n* Presence of active systemic infections.\n* History of or active primary\u002Fsecondary immunodeficiency.\n* Participation in an interventional clinical trial within 1 month prior to screening.\n* Hypersensitivity to any component of the study drug (and its excipients).\n* Any condition deemed by the investigator to pose excessive risk, confound results, or interfere with compliance.","ALL","18 Years","75 Years",{"count":75,"type":76},18,"ESTIMATED","INTERVENTIONAL",[79],"PHASE1","This Phase Ib clinical trial aims to evaluate the safety, tolerability, and preliminary efficacy of JMKX000189 tablets in participants with chemotherapy-induced peripheral neuropathy (CIPN).",[82],"CIPN - Chemotherapy-Induced Peripheral Neuropathy","NOT_YET_RECRUITING","2026-05-15",{"date":86,"type":87},"2026-05-22","ACTUAL",{"date":89,"type":76},"2026-05-10",{"date":91,"type":76},"2027-06-20",{"name":5,"class":6},1]